European Commission approves Roche’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
Posted:
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted marketing authorisation for Tecentriq® SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer immunotherapy for subcutaneous (under the skin) injection.
Wearable medical devices are changing healthcare delivery by shifting care beyond traditional settings and bringing it closer to patients’ daily lives. By offering continuous monitoring, promoting patient engagement and supporting remote interventions, these technologies are becoming an essential part of…
Attendees
Sponsors and Exhibitors
Agenda 2025
Contact us